Processa Pharmaceuticals, Inc. Cost of Goods Sold (Deprecated 2018-01-31)
Processa Pharmaceuticals, Inc. (PCSA) reported Cost of Goods Sold (Deprecated 2018-01-31) of $125.88 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2017-09-25.
Discontinued › Expense Statement
us-gaap:CostOfGoodsSold · last filed 2017-09-25
- Processa Pharmaceuticals, Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2015-12-31 was $58.29K.
- Processa Pharmaceuticals, Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2015-09-30 was $42.62K, a 68.52% increase year-over-year.
- Processa Pharmaceuticals, Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2015-06-30 was $11.01K, a 84.32% decline year-over-year.
- Processa Pharmaceuticals, Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2015-03-31 was $24.97K, a 173.15% increase year-over-year.
- Processa Pharmaceuticals, Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2015 was $125.88K, a 88.34% increase from fiscal 2014.
- Processa Pharmaceuticals, Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $66.83K, a 64.45% decline from fiscal 2013.
- Processa Pharmaceuticals, Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2013 was $188.00K, a 41.08% increase from fiscal 2012.
- Processa Pharmaceuticals, Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2012 was $133.25K.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 3 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 12 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month as first filed | Cost of Goods Sold (Deprecated 2018-01-31) 27 month | Cost of Goods Sold (Deprecated 2018-01-31) 30 month | Cost of Goods Sold (Deprecated 2018-01-31) 33 month | Cost of Goods Sold (Deprecated 2018-01-31) 36 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015-12-31 | $58.29K derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-25 | $100.91K derived: sum of 2 quarters · filed 2017-09-25 | $111.92K derived: sum of 3 quarters · filed 2017-09-25 | $125.88K 10-K · filed 2017-09-25 | ||||||||
| 2015-09-30 | $42.62K 10-Q · filed 2017-09-08 | $53.63K derived: sum of 2 quarters · filed 2017-09-08 | $67.58K 10-Q · filed 2017-09-08 | $82.89K 10-Q · filed 2015-12-01 | $40.80K derived: sum of 4 quarters · filed 2017-09-08 | |||||||
| 2015-06-30 | $11.01K 10-Q · filed 2015-08-19 | $24.97K 10-Q · filed 2017-08-30 | $40.28K 10-Q · filed 2015-08-19 | -$1.81K derived: sum of 3 quarters · filed 2017-08-07 | $23.47K derived: sum of 4 quarters · filed 2017-08-07 | |||||||
| 2015-03-31 | $24.97K 10-Q · filed 2017-08-07 | $29.27K 10-Q · filed 2015-05-15 | -$12.82K derived: sum of 2 quarters · filed 2017-08-07 | $12.47K derived: sum of 3 quarters · filed 2017-08-07 | $82.66K derived: sum of 4 quarters · filed 2017-08-07 | |||||||
| 2014-12-31 | -$37.79K derived: 10-K 12 month − 10-Q 9 month · filed 2017-06-19 | -$12.50K derived: sum of 2 quarters · filed 2017-06-19 | $57.69K derived: sum of 3 quarters · filed 2017-06-19 | $66.83K 10-K · filed 2017-06-19 | $113.25K 10-K · filed 2015-04-14 | |||||||
| 2014-09-30 | $25.29K 10-Q · filed 2015-12-01 | $95.48K derived: sum of 2 quarters · filed 2015-12-01 | $104.62K 10-Q · filed 2015-12-01 | $138.52K derived: sum of 4 quarters · filed 2015-12-01 | ||||||||
| 2014-06-30 | $70.19K 10-Q · filed 2015-08-19 | $79.33K 10-Q · filed 2015-08-19 | $113.23K derived: sum of 3 quarters · filed 2015-08-19 | $193.68K derived: sum of 4 quarters · filed 2015-08-19 | ||||||||
| 2014-03-31 | $9.14K 10-Q · filed 2015-05-15 | $43.04K derived: sum of 2 quarters · filed 2015-05-15 | $123.49K derived: sum of 3 quarters · filed 2015-05-15 | $185.02K derived: sum of 4 quarters · filed 2015-05-15 | $330.40K 10-Q · filed 2014-05-14 | |||||||
| 2013-12-31 | $33.90K derived: 10-K 12 month − 10-Q 9 month · filed 2015-04-14 | $114.35K derived: sum of 2 quarters · filed 2015-04-14 | $175.88K derived: sum of 3 quarters · filed 2015-04-14 | $188.00K 10-K · filed 2015-04-14 | $321.26K 10-K · filed 2014-03-27 | |||||||
| 2013-09-30 | $80.45K 10-Q · filed 2014-11-13 | $141.97K derived: sum of 2 quarters · filed 2014-11-13 | $154.10K 10-Q · filed 2014-11-13 | $187.21K derived: sum of 4 quarters · filed 2014-11-13 | $287.36K 10-Q · filed 2013-11-08 | |||||||
| 2013-06-30 | $61.52K 10-Q · filed 2014-08-19 | $73.65K 10-Q · filed 2014-08-19 | $106.76K derived: sum of 3 quarters · filed 2014-08-19 | $140.67K derived: sum of 4 quarters · filed 2014-08-19 | $206.91K 10-Q/A · filed 2013-09-06 | |||||||
| 2013-03-31 | $12.13K 10-Q · filed 2014-05-14 | $45.23K derived: sum of 2 quarters · filed 2014-05-14 | $79.15K derived: sum of 3 quarters · filed 2014-05-14 | $132.97K derived: sum of 4 quarters · filed 2014-05-14 | ||||||||
| 2012-12-31 | $33.11K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | $67.02K derived: sum of 2 quarters · filed 2014-03-27 | $120.85K derived: sum of 3 quarters · filed 2014-03-27 | $133.25K 10-K · filed 2014-03-27 | ||||||||
| 2012-09-30 | $33.92K 10-Q · filed 2013-11-08 | $87.74K derived: sum of 2 quarters · filed 2013-11-08 | $100.15K 10-Q · filed 2013-11-08 | |||||||||
| 2012-06-30 | $53.83K 10-Q/A · filed 2013-09-06 | $66.23K 10-Q/A · filed 2013-09-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |